DoW Vision, Clinical Trial Award
Summary: The fiscal year 2026 (FY26) Vision Research Program (VRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of service-connected eye injury and visual dysfunction. Offered by Defense Health Agency Contracting Activity - DHACA; awards $2.6M; applications due November 12, 2026.
Key Facts
- Funder
- Defense Health Agency Contracting Activity - DHACA
- Award amount
- $2.6M
- Deadline
- November 12, 2026
- Geography
- United States
- Categories
- Research
- Status
- Open
About This Grant
Summary: The fiscal year 2026 (FY26) Vision Research Program (VRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of service-connected eye injury and visual dysfunction. Research must align with at least one of the FY26 VRP Focus Areas . Distinctive Features: · For interventions that require Investigational New Drug (IND)/Investigational...
Full requirements and application instructions: official listing.
Similar Open Grants
DoW Neurofibromatosis Investigator-Initiated Research Award
Defense Health Agency Contracting Activity - DHACA
DoW Neurofibromatosis Research Academy – Scholar Award
Defense Health Agency Contracting Activity - DHACA
DoW Neurofibromatosis Exploration-Hypothesis Development Award
Defense Health Agency Contracting Activity - DHACA
DoW Neurofibromatosis Synergistic Idea Award
Defense Health Agency Contracting Activity - DHACA
DoW Duchenne Muscular Dystrophy, Clinical/Translational Research Award
Defense Health Agency Contracting Activity - DHACA
DOW Combat Readiness – Medical Research Program Translational Research Award
Defense Health Agency Contracting Activity - DHACA
DoW Vision, Investigator-Initiated Research Award
Defense Health Agency Contracting Activity - DHACA
DoW Vision, Translational Research Award
Defense Health Agency Contracting Activity - DHACA
ROSES 2025: C.2 Solar System Science
NASA Headquarters
NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required)
National Institutes of Health